Phylonix received a broad US patent for its zebrafish-based assays to assess cardiac functions and toxicity. The company's eZ-ScreenTM technology enables thorough assessment of cardiotoxicity during early stages of drug development, leveraging the speed and cost-effectiveness of the zebrafish model.
Phylonix Pharmaceuticals has been awarded a Phase II SBIR grant from the NIH to develop high-throughput in vivo zebrafish assays for assessing Cytochrome P450 drug metabolism and safety. The assay will accelerate drug metabolism and safety profiling, reducing costly late-stage development failures.
Phylonix Pharmaceuticals has been awarded a Phase II SBIR grant from the National Eye Institute to develop zebrafish models for eye diseases. The company aims to model various eye diseases, including diabetic retinopathy and age-related macular degeneration, using zebrafish models with high accuracy and speed.
Phylonix Pharmaceuticals received a $500,000 NSF Phase II SBIR grant to evaluate the toxic effects of industrial chemicals on human organ development in zebrafish. Preliminary data show a correlation between zebrafish results and mammalian findings.